Intra-Cellular Therapies Inc. (ITCI) to Post FY2016 Earnings of ($2.73) Per Share, SunTrust Banks Forecasts
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) – Equities research analysts at SunTrust Banks increased their FY2016 EPS estimates for shares of Intra-Cellular Therapies in a research note issued on Wednesday. SunTrust Banks analyst E. Nash now forecasts that the brokerage will post earnings per share of ($2.73) for the year, up from their prior forecast of ($2.84). SunTrust Banks currently has a “Neutral” rating and a $15.00 price target on the stock. SunTrust Banks also issued estimates for Intra-Cellular Therapies’ Q4 2016 earnings at ($0.69) EPS, FY2017 earnings at ($3.02) EPS, FY2018 earnings at ($2.57) EPS, FY2019 earnings at ($2.15) EPS and FY2020 earnings at ($2.47) EPS.
Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.14. The firm had revenue of $4.36 million for the quarter, compared to the consensus estimate of $0.04 million. The business’s revenue for the quarter was up NaN% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.91) earnings per share.
Other research analysts have also recently issued research reports about the company. Piper Jaffray Cos. set a $22.00 price objective on Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Monday, October 10th. Leerink Swann restated a “buy” rating and issued a $95.00 price target on shares of Intra-Cellular Therapies in a research report on Thursday, August 11th. Cowen and Company restated a “buy” rating and issued a $75.00 price target on shares of Intra-Cellular Therapies in a research report on Friday, August 5th. Zacks Investment Research upgraded Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Friday. Finally, JMP Securities cut Intra-Cellular Therapies from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. Intra-Cellular Therapies presently has an average rating of “Hold” and a consensus price target of $42.00.
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) opened at 14.30 on Monday. Intra-Cellular Therapies has a one year low of $10.80 and a one year high of $59.96. The firm’s 50-day moving average price is $15.82 and its 200 day moving average price is $33.16. The company’s market capitalization is $618.73 million.
Hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its stake in Intra-Cellular Therapies by 23.1% in the second quarter. Royal Bank of Canada now owns 2,684 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 504 shares during the period. Bank of Montreal Can acquired a new stake in Intra-Cellular Therapies during the second quarter valued at $155,000. KCG Holdings Inc. acquired a new stake in Intra-Cellular Therapies during the third quarter valued at $168,000. Mycio Wealth Partners LLC raised its stake in Intra-Cellular Therapies by 14.3% in the second quarter. Mycio Wealth Partners LLC now owns 4,398 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 550 shares during the period. Finally, Teacher Retirement System of Texas raised its stake in Intra-Cellular Therapies by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 4,532 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 546 shares during the period. 65.39% of the stock is currently owned by institutional investors and hedge funds.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Stock Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related stocks with our FREE daily email newsletter.